to repeated courses of 5FU did not develop resistance. So, 5FU was destined to join methotrexate that prevents purine synthesis by blocking the enzyme dihydrofolate reductase and alkylating agents like the prodrug cyclophosphamide, which alkylates the "double helix" (1) .
Strategies for the treatment of breast cancer were simultaneously evolving in two directions. First, combination cytotoxic chemotherapy was proven to be effective to create cures in childhood leukemia, so using combination chemotherapy for the treatment of solid tumors to hit multiple targets, kill optimally, and retard the development of drug resistance seemed prudent. The late Gianni Bonadonna tells the story in his Karnofsky Memorial Lecture (6) that in May 1972, he met Paul P. Carbone at the NCI, who showed him the remarkable response rate of combination cyclophosphamide, methotrexate, 5FU, and prednisone (CMFP) in metastatic breast cancer. There were 20% complete remissions and 40% partial remissions with a median duration of response of 8 months (6). Bonadonna, with the full support of Pietro Buscalossi and Umberto Veronesi, repeated the CMF regimen in metastatic breast cancer but deleted the P, obtaining a 57% response rate (6) . This, now the classic CMF regimen, was used successfully to treat metastatic disease. Second, the major conceptual advance was the use of combination cytotoxic chemotherapy as an adjuvant following surgery to destroy scattered subclinical micrometastases. Bonadonna's first report (7) demonstrated that treatment failure occurred in 24% of 176 control patients but in only 5.3% of 207 women given combination chemotherapy after 27 months. Bonadonna's update in his Karnofsky lecture (6) demonstrated that the relapse-free survival of 109 months and total survival was not yet achieved and was extraordinarily large in premenopausal patients at 14 years. These data were compared with postmenopausal patients with a relapse-free survival and overall survival of 43 months and 36 months, respectively. These advances in clinical care would not have occurred but for the era of rational drug design to target the mechanisms of cell replication through DNA synthesis. 5FU was a pivotal cornerstone in that story. However, it was a strategy that was destined to fail because of a lack of tumor specificity. Normal replicating cells were equally vulnerable to inhibitors of DNA synthesis, with severe side effects and toxicity in the colon and hematologic disorders with immune suppression. Changes had to occur, and Harold Rusch was a great man who walked with Presidents. He said that he had doubts that he had not spent more time considering the treatment of cancer rather than the cause. He was angry and depressed at the unanticipated turn of events in his life. I was unaware of the burden he was carrying in 1977 when I spent 3 months at the Wisconsin Clinical Cancer Center and he asked me to tell him all about tamoxifen and my strategy to create a longterm adjuvant targeted therapy for the treatment of breast cancer (9) . Tamoxifen, at that time, was not even FDA approved for the treatment of metastatic breast cancer in the United States of America. That landmark was only to occur on December 29, 1977. I was recruited by Paul Carbone and Harold to come to the brand new Wisconsin Clinical Cancer Center in 1980. Harold and I had offices next to each other and I was mentored by him each day in techniques of leadership in Cancer Centers. We were friends, but when he was diagnosed with prostate cancer, Harold prepared for his memorial service. I was truly honored to be one of those invited to speak at Harold's memorial service. I took the initiative to write to President Ronald Reagan to request a letter recognizing the extraordinary contributions of Harold Rusch as a leader in cancer research for our nation. He was given the citation by Chancellor Donna Shalala and me at his home, just before he died on May 26, 1988. I chose to read the letter from the President at Harold's memorial service.
Through 1950-64) ], medicine moved from rational drug design to disrupt DNA synthesis (3) (4) (5) to the first targeted therapy for the treatment and prevention of breast cancer (9) . I was subsequently invited to write a retrospective of Harold's contribution in advancing cancer research, which I was honored to do. It is entitled "Harold P. Rusch, MD and the UW Madison -A Tale of Two Cancer Centers" (10) . 5FU, the initial success story in the treatment of cancer at Wisconsin, passed the baton 25 years later to the development of tamoxifen, the first target treatment and preventive for any cancer (9) . The progress with tamoxifen at Wisconsin to save lives is a result of the opportunities immediately recognized by Paul Carbone and Harold Rusch once the "War on Cancer" had been declared.
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